EMAIL THIS PAGE TO A FRIEND

PloS one

Antibiotic exposure in a low-income country: screening urine samples for presence of antibiotics and antibiotic resistance in coagulase negative staphylococcal contaminants.


PMID 25462162

Abstract

Development of antimicrobial resistance has been assigned to excess and misuse of antimicrobial agents. Staphylococci are part of the normal flora but are also potential pathogens that have become essentially resistant to many known antibiotics. Resistances in coagulase negative staphylococci (CoNS) are suggested to evolve due to positive selective pressure following antibiotic treatment. This study investigated the presence of the nine most commonly used antimicrobial agents in human urine from outpatients in two hospitals in Ghana in relation to CoNS resistance. Urine and CoNS were sampled (n = 246 and n = 96 respectively) from patients in two hospitals in Ghana. CoNS were identified using Gram staining, coagulase test, and MALDI-TOF/MS, and the antimicrobial susceptibility to 12 commonly used antimicrobials was determined by disk diffusion. Moreover an analytical method was developed for the determination of the nine most commonly used antimicrobial agents in Ghana by using solid-phase extraction in combination with HPLC-MS/MS using electron spray ionization. The highest frequency of resistance to CoNS was observed for penicillin V (98%), trimethoprim (67%), and tetracycline (63%). S. haemolyticus was the most common isolate (75%), followed by S. epidermidis (13%) and S. hominis (6%). S. haemolyticus was also the species displaying the highest resistance prevalence (82%). 69% of the isolated CoNS were multiple drug resistant (≧ 4 antibiotics) and 45% of the CoNS were methicillin resistant. Antimicrobial agents were detected in 64% of the analysed urine samples (n = 121) where the most frequently detected antimicrobials were ciprofloxacin (30%), trimethoprim (27%), and metronidazole (17%). The major findings of this study was that the prevalence of detected antimicrobials in urine was more frequent than the use reported by the patients and the prevalence of resistant S. haemolyticus was more frequent than other resistant CoNS species when antimicrobial agents were detected in the urine.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

34218
Cefuroxime, VETRANAL, analytical standard
C16H16N4O8S
C1200000
Chloramphenicol, European Pharmacopoeia (EP) Reference Standard
C11H12Cl2N2O5
31667
Chloramphenicol, VETRANAL, analytical standard
C11H12Cl2N2O5
23276
Chloramphenicol, tested according to Ph.Eur.
C11H12Cl2N2O5
17850
Ciprofloxacin, ≥98.0% (HPLC)
C17H18FN3O3
PHR1167
Ciprofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material
C17H18FN3O3
Y0000198
Ciprofloxacin, European Pharmacopoeia (EP) Reference Standard
C17H18FN3O3
E6376
Erythromycin, potency: ≥850 μg per mg
C37H67NO13
E5389
Erythromycin, BioReagent, suitable for cell culture
C37H67NO13
45674
Erythromycin, tested according to Ph.Eur.
C37H67NO13
PHR1039
Erythromycin, Pharmaceutical Secondary Standard; Certified Reference Material
C37H67NO13
E1300000
Erythromycin, for microbiological assay, European Pharmacopoeia (EP) Reference Standard
C37H67NO13
1242000
Erythromycin, United States Pharmacopeia (USP) Reference Standard
C37H67NO13
E0774
Erythromycin, meets USP testing specifications
C37H67NO13
E4514
Erythromycin, plant cell culture tested, ~98%
C37H67NO13
45703
Erythromycin standard solution, 1 mg/mL in H2O
C37H67NO13
F0756
Fusidic acid
C31H48O6
Y0001411
Fusidic acid, European Pharmacopoeia (EP) Reference Standard
C31H48O6
Y0001394
Fusidic acid for peak identification, European Pharmacopoeia (EP) Reference Standard
C31H48O6
M3761
Metronidazole, analytical standard
C6H9N3O3
M1547
Metronidazole, BioXtra
C6H9N3O3
46461
Metronidazole, VETRANAL, analytical standard
C6H9N3O3
M1850000
Metronidazole, European Pharmacopoeia (EP) Reference Standard
C6H9N3O3
PHR1052
Metronidazole, Pharmaceutical Secondary Standard; Certified Reference Material
C6H9N3O3
46713
Rifampicin, VETRANAL, analytical standard
C43H58N4O12
R0700000
Rifampicin, European Pharmacopoeia (EP) Reference Standard
C43H58N4O12
S7507
Sulfamethoxazole, analytical standard
C10H11N3O3S
76177
Sulfamethoxazole, certified reference material, TraceCERT®
C10H11N3O3S
31737
Sulfamethoxazole, VETRANAL, analytical standard
C10H11N3O3S
PHR1126
Sulfamethoxazole, Pharmaceutical Secondary Standard; Certified Reference Material
C10H11N3O3S